Back to top
more

MannKind (MNKD)

(Delayed Data from NSDQ)

$4.32 USD

4.32
1,897,795

+0.01 (0.23%)

Updated May 10, 2024 04:00 PM ET

After-Market: $4.32 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for MNKD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

MannKind Corporation [MNKD]

Reports for Purchase

Showing records 101 - 120 ( 228 total )

Company: MannKind Corporation

Industry: Medical - Biomedical and Genetics

Record: 101

03/13/2015

Industry Report

Pages: 18

Recent Drug Launch Weekly Retail Sales Tracker - Week Ended March 6

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: MannKind Corporation

Industry: Medical - Biomedical and Genetics

Record: 102

02/26/2015

Company Report

Pages: 7

Price: 24.95

Company: MannKind Corporation

Industry: Medical - Biomedical and Genetics

Record: 103

02/25/2015

Company Report

Pages: 8

Afrezza Debuts - Strategic Plans Emerge

Provider: Griffin Securities, Inc.

Analyst: MARKEY K

Price: 25.00

Research Provided by a Third Party

Company: MannKind Corporation

Industry: Medical - Biomedical and Genetics

Record: 104

02/11/2015

Daily Note

Pages: 4

Discontinuation of Coverage of the Biotech Sector

Provider: Brinson Patrick Securities Corporation

Price: 10.00

Research Provided by a Third Party

Company: MannKind Corporation

Industry: Medical - Biomedical and Genetics

Record: 105

02/03/2015

Company Report

Pages: 4

Afrezza Makes Its Debut

Provider: Griffin Securities, Inc.

Analyst: MARKEY K

Price: 10.00

Research Provided by a Third Party

Company: MannKind Corporation

Industry: Medical - Biomedical and Genetics

Record: 106

01/12/2015

Company Report

Pages: 4

A Smooth Transition as Commercialization Nears.

Provider: Griffin Securities, Inc.

Analyst: MARKEY K

Price: 10.00

Research Provided by a Third Party

Company: MannKind Corporation

Industry: Medical - Biomedical and Genetics

Record: 107

01/09/2015

Company Report

Pages: 6

Price: 24.95

Company: MannKind Corporation

Industry: Medical - Biomedical and Genetics

Record: 108

11/05/2014

Company Report

Pages: 7

Price: 24.95

Company: MannKind Corporation

Industry: Medical - Biomedical and Genetics

Record: 109

11/04/2014

Company Report

Pages: 5

Financial results come in as expected

Provider: Griffin Securities, Inc.

Analyst: MARKEY K

Price: 10.00

Research Provided by a Third Party

Company: MannKind Corporation

Industry: Medical - Biomedical and Genetics

Record: 110

10/28/2014

Company Report

Pages: 8

Price: 24.95

Company: MannKind Corporation

Industry: Medical - Biomedical and Genetics

Record: 111

08/18/2014

Company Report

Pages: 9

2Q''14 Update; Model Changes from SNY Deal

Provider: Brinson Patrick Securities Corporation

Analyst: JAMES C

Price: 25.00

Research Provided by a Third Party

Company: MannKind Corporation

Industry: Medical - Biomedical and Genetics

Record: 112

08/13/2014

Company Report

Pages: 7

Price: 24.95

Company: MannKind Corporation

Industry: Medical - Biomedical and Genetics

Record: 113

08/11/2014

Company Report

Pages: 8

Target Price Change : Pharmaceuticals

Provider: Griffin Securities, Inc.

Analyst: MARKEY K

Price: 25.00

Research Provided by a Third Party

Company: MannKind Corporation

Industry: Medical - Biomedical and Genetics

Record: 114

08/11/2014

Company Report

Pages: 9

Global Sanofi Deal: Finds Ideal Strategic Partner

Provider: Brinson Patrick Securities Corporation

Analyst: JAMES C

Price: 25.00

Research Provided by a Third Party

Company: MannKind Corporation

Industry: Medical - Biomedical and Genetics

Record: 115

07/09/2014

Company Report

Pages: 7

Price: 24.95

Company: MannKind Corporation

Industry: Medical - Biomedical and Genetics

Record: 116

06/30/2014

Company Report

Pages: 10

A Giant Leap - FDA approves Afrezza for type 1 and type 2 diabetes

Provider: Griffin Securities, Inc.

Analyst: MARKEY K

Price: 25.00

Research Provided by a Third Party

Company: MannKind Corporation

Industry: Medical - Biomedical and Genetics

Record: 117

06/30/2014

Company Report

Pages: 11

Raising Price Target to $15.00 on FDA approval of Afrezza

Provider: Brinson Patrick Securities Corporation

Analyst: JAMES C

Price: 25.00

Research Provided by a Third Party

Company: MannKind Corporation

Industry: Medical - Biomedical and Genetics

Record: 118

05/19/2014

Company Report

Pages: 14

1Q''14 Update: Eagerly Anticipating Afrezza Approval.

Provider: Brinson Patrick Securities Corporation

Analyst: JAMES C

Price: 50.00

Research Provided by a Third Party

Company: MannKind Corporation

Industry: Medical - Biomedical and Genetics

Record: 119

05/15/2014

Company Report

Pages: 14

1Q''14 Update: Eagerly Anticipating Afrezza Approval

Provider: Brinson Patrick Securities Corporation

Analyst: JAMES C

Price: 50.00

Research Provided by a Third Party

Company: MannKind Corporation

Industry: Medical - Biomedical and Genetics

Record: 120

05/14/2014

Company Report

Pages: 7

Price: 24.95